Altered urothelial ATP signalling in major subset of human overactive bladder patients with pyuria.

Altered urothelial ATP signalling in major subset of human overactive bladder patients with pyuria. Am J Physiol Renal Physiol. 2016 Jun 29;:ajprenal.00339.2015 Authors: Contreras-Sanz A, Krska L, Balachandran AA, Curtiss NL, Khasriya R, Kelley S, Strutt M, Gill HS, Taylor KM, Mansfield KJ, Wu C, Peppiatt-Wildman CM, Malone-Lee J, Duckett J, Wildman SS Abstract RATIONALE: Overactive Bladder (OAB) is an idiopathic condition, characterized by urgency, urinary frequency and urgency incontinence, in the absence of routinely traceable urinary infection. We have described microscopic pyuria (≥10 wbc μl-1) in patients suffering from the worst symptoms. It is established that inflammation is associated with increased ATP release from epithelial cells, and extracellular ATP originating from the urothelium following increased hydrostatic pressure, is a mediator of bladder sensation. OBJECTIVES: Here, using bladder-biopsy samples, we have investigated urothelial ATP signaling in OAB patients with microscopic pyuria. FINDINGS: Basal, but not stretch-evoked, release of ATP was significantly greater from urothelium of OAB patients with pyuria than from non-OAB patients or OAB patients without pyuria (
Source: Am J Physiol Renal P... - Category: Urology & Nephrology Authors: Tags: Am J Physiol Renal Physiol Source Type: research

Related Links:

AbstractPurpose of ReviewTo provide an overview of the appropriate evaluation of elderly men with urinary incontinence and an updated review of treatment options available to these patients.Recent FindingsAdding pelvic floor physical therapy to bladder training exercises is more effective for treating overactive bladder than bladder training alone. Beta-3 adrenergic agonists are a safe and effective alternative to anticholinergic therapy in older adults. Sacral neuromodulation is safe and effective in older adults and may benefit men with incomplete bladder emptying. A de-obstructing surgery may benefit men with both under...
Source: Current Geriatrics Reports - Category: Geriatrics Source Type: research
Axonics Not Intimidated by Medtronic Axonics' implantable rechargeable sacral neuromodulation device is now FDA-approved for the treatment of fecal incontinence, overactive bladder, and urinary retention. Medtronic is suing Axonics for alleged patent infringement, but the company does not appear to be intimidated.   Thermo Fisher May Fancy Qiagen The rumor mill was lit with a recent Bloomberg report of a potential $8 billion Thermo Fisher-Qiagen deal. Qiagen acknowledged that it has received several "indications of interest" but t...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
CONCLUSION: These concepts of PRO and GAS open up a new domain in the evaluation of treatments, with a subjective view of the results. They deserve to be integrated into the usual, objective evaluations, in order to adapt the treatment of the patients, according to the real impact of the treatment. PMID: 31744687 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
For 22 years, the world's largest pure-play medical device company was the only player in sacral neuromodulation, a space that addresses urinary problems as well as fecal incontinence. Now there's a new kid on the block, which has created quite an intense David vs. Goliath medtech story. For those unfamiliar with the Axonics vs. Medtronic story up to this point, click here for a quick rundown of recent events that have transpired in this market.   FDA Approves Second Indication for Axonics r-SNM FDA approved the urinary indications for an implantable rechargeable sacral neuro...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Implants Source Type: news
In conclusion, limited evidence shows that routine urodynamics prior to non-surgical management of UI or surgical management of SUI is not associated with improved treatment outcomes, when compared to clinical evaluation only. Well-designed clinical trials are needed to evaluate the clinical and cost-effectiveness of routine urodynamics prior to surgical management of SUI and OAB.
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
ConclusionsMirabegron efficacy, safety, and tolerability over 12 wk were confirmed in patients aged ≥65 yr with OAB and incontinence.Patient summaryWe examined the effect of mirabegron compared with placebo in people aged 65 yr or older with overactive bladder and incontinence. Mirabegron improved the symptoms of overactive bladder compared with placebo. Side effects were similar to those already known for mirabegron.
Source: European Urology - Category: Urology & Nephrology Source Type: research
Review in-depth clinical information, latest medical news, and guidelines on urinary incontinence, urge incontinence, and adult incontinence. Read about overactive bladder (OAB) and overactive bladder treatment.
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Resource Center Source Type: news
Authors: Tae BS, Park TY, Jeon BJ, Chung H, Lee YH, Park JY, Bae JH, Choi H Abstract Purpose: To evaluate seasonal variations of overactive bladder (OAB) symptoms in women who visited hospital clinics. Methods: Medical records of female patients treated for OAB symptoms from January 2011 to December 2017 were retrospectively reviewed. Patients with pyuria at the first visit, those who did not complete the questionnaire, and those with
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
We report on our experience with pelvic floor physical therapy (PFPT) with or without myofascial release as treatment for women with symptoms of urinary urgency or urge incontinence.
Source: Journal of Bodywork and Movement Therapies - Category: Physiotherapy Authors: Source Type: research
The medical device industry has seen its share of David vs. Goliath stories over the years, but few have been as intense as the battle between Medtronic and Axonics over the sacral neuromodulation (SNM) market. The story took an unexpected turn this week as Medtronic slapped Axonics with a patent infringement lawsuit that is likely to take years to play out. Medtronic (the Goliath of this story), filed a lawsuit against Axonics Modulation Technologies (the David of the story), alleging infringement of four patents related to Medtronic's SNM lead placement procedure and implant recharging technologie...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Implants Source Type: news
More News: Incontinence | Overactive Bladder | Overactive Bladder Syndrome | Urology & Nephrology